Biogen BIIB Royalty and other revenue — Total Revenue

Other product segments

Similar metrics at other companies

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

HRBRoyalty, product and other revenues — Total revenues

$171.78M-3.3%

BMRNRoyalty and other revenues — Total revenues

$6.13M-41.6%

NVAXLicensing, royalties, and other — Total Revenue

$97.31M+116%

NVAXRoyalties — Total Revenue

$3.52M—

GERNRoyalties — Total revenues

$66K-60.5%

Questions, answered.

What is Biogen's royalty and other revenue — total revenue?

Biogen (BIIB) reported royalty and other revenue — total revenue of $9.7M in Q1 2026.

How has Biogen's royalty and other revenue — total revenue changed year-over-year?

Biogen's royalty and other revenue — total revenue decreased by 11.8% year-over-year, from $11M to $9.7M.

What is the long-term trend for Biogen's royalty and other revenue — total revenue?

Over 4 years (2021 to 2025), Biogen's royalty and other revenue — total revenue has grown at a 2.4% compound annual growth rate (CAGR), from $48.6M to $53.5M.

What does royalty and other revenue — total revenue mean?

This metric represents the total revenue generated from royalty streams, licensing agreements, and ancillary service arrangements within a specific business segment. It captures income derived from intellectual property rights where the company receives payments based on the sales performance of products commercialized by third-party partners. This revenue stream is distinct from direct product sales and reflects the monetization of the company's research and development pipeline through strategic partnerships.